St. Jude Medical (St. Paul, Minnesota) reported the enrollment of the first patient in the EnligHTN III trial, a study evaluating the safety and performance of the new second-generation EnligHTN Renal Denervation System in patients with drug-resistant, uncontrolled hypertension. Read More
